Full text is available at the source.
Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
How GLP-1 Receptor Agonists May Affect Liver Disease Linked to Alcohol Use Disorder
AI simplified
Abstract
GLP-1 receptor agonists (GLP-1RAs) are associated with a significantly lower risk of developing alcohol-related liver disease (ArLD) in patients with alcohol use disorder (AUD).
- In patients with AUD, the incidence rate of ArLD was 6.0 per 1000 person-years for GLP-1RA users compared to 8.7 for DPP-4 inhibitor users.
- The hazard ratio for developing ArLD in GLP-1RA users was 0.62, indicating a lower risk compared to DPP-4 users.
- GLP-1RA users also had a reduced risk of all-cause mortality (HR: 0.53) in the AUD cohort.
- Among patients with established ArLD, GLP-1RA users had an incidence rate of hepatic decompensation of 39.5 per 1000 person-years versus 51.4 for DPP-4 users.
- The hazard ratio for hepatic decompensation in GLP-1RA users was 0.66, reflecting a lower risk when compared to DPP-4 users.
AI simplified